ichorbio has released five new biosimilars targeting PD-1 and PD-L1. The biosimilars are as follows:
Sintilimab Biosimilar – Research Grade [ICH5001]
Toripalimab Biosimilar – Research Grade [ICH5002]
Camrelizumab – Research Grade [ICH5003]
Tislelizumab Biosimilar – Research Grade [ICH5004]
Durvalumab Biosimilar – Research Grade [ICH5052]